Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Liver Diseases

Free Subscription 27.10.2025 1 Am J Gastroenterol 1 Am J Pathol 3 BMC Cancer 3 BMC Gastroenterol 2 Dig Dis Sci 3 Endoscopy 2 Eur Radiol 1 Gastroenterology 1 Gastrointest Endosc 1 Gut 4 Hepatology 2 Indian J Gastroenterol 3 Int J Cancer 3 J Gastroenterol 1 J Gastroenterol Hepatol 12 J Hepatol 2 Lancet 1 Minerva Gastroenterol (Torino) 3 PLoS One 1 Proc Natl Acad Sci U S A 1 Radiology 3 Transplantation

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Gastroenterol

1. DE FARIA MORAES B, Pedral Diniz Leite GA, Pedral Diniz Leite GA, Motta Fonseca ML, et al
   Reevaluating the Role of Proton Pump Inhibitors After Endoscopic Band Ligation of Esophageal Varices in Cirrhotic Patients: A Systematic Review and Meta-analysis.
   Am J Gastroenterol. 2025 Oct 21. doi: 10.14309/ajg.0000000000003800.
   PubMed         Abstract available
   
   

   
   Am J Pathol

2. CACERES A, Shibata NM, Davalos-Gutierrez CD, Sarode GV, et al
   Inactivation of Atp7b copper transporter in intestinal epithelial cells is associated with altered lipid processing and cell growth machinery independent from hepatic copper accumulation and severity of liver histology.
   Am J Pathol. 2025 Oct 16:S0002-9440(25)00379.
   PubMed         Abstract available
   
   

   
   BMC Cancer

3. NONG X, Yao Y, Xie J, Liang J, et al
   Preliminary experience of lenvatinib, tislelizumab and transcatheter arterial chemoembolization for BCLC stage C hepatocellular carcinoma: a phase II study.
   BMC Cancer. 2025;25:1631.
   PubMed         Abstract available
   
   
4. LUO Y, Zhang G, Zhong S, Chen S, et al
   Deep multi-instance learning model based on gadoxetic acid-enhanced MRI for predicting microvascular invasion of hepatocellular carcinoma: a multicenter, retrospective study.
   BMC Cancer. 2025;25:1626.
   PubMed         Abstract available
   
   
5. HOU S, Hu S, Wu Q, Sun H, et al
   Efficacy and safety of stereotactic body radiation therapy combined with targeted agents and immunotherapies in hepatocellular carcinoma: a systematic review and meta-analysis.
   BMC Cancer. 2025;25:1602.
   PubMed         Abstract available
   
   

   
   BMC Gastroenterol

6. ELSABAAWY M, Afify S, Othman W, Ragab A, et al
   Frailty and liver transplant eligibility beyond MELD scores: integrating functional status into candidate selection.
   BMC Gastroenterol. 2025;25:743.
   PubMed         Abstract available
   
   
7. AGHAZADEH MH, Azizmohammad Looha M, Khaleghjoo Y, Ghoorchi Beigi F, et al
   Mortality risk prediction in liver transplant candidates: a prognostic model using key clinical variables.
   BMC Gastroenterol. 2025;25:745.
   PubMed         Abstract available
   
   
8. YANG X, Wang G, Gao L, Chen J, et al
   Lactate-to-glucose ratio and short-term all-cause mortality in critically ill cirrhosis patients: a MIMIC-IV and eICU-CRD database study.
   BMC Gastroenterol. 2025;25:750.
   PubMed        
   
   

   
   Dig Dis Sci

9. BHATI G, Bhati K, Gupta A, Bansal R, et al
   Hitting the Nail on the Head: A Laparoscopic Retrieval of a Metallic Intrahepatic Foreign Body.
   Dig Dis Sci. 2025 Oct 22. doi: 10.1007/s10620-025-09477.
   PubMed         Abstract available
   
   
10. ISMAIL A, Abusuliman M, Kloub M, Abbarh S, et al
    Comparative Risk of Recurrent Esophageal Variceal Hemorrhage and Other Decompensation Events with Carvedilol Versus Propranolol in Patients with Cirrhosis: A Retrospective Study.
    Dig Dis Sci. 2025 Oct 18. doi: 10.1007/s10620-025-09453.
    PubMed         Abstract available
    
    

    
    Endoscopy

11. YAMAMOTO K, Tsuchiya T, Tonozuka R, Mukai S, et al
    Endoluminal radiofrequency ablation for ingrowth occlusion after endoscopic ultrasound-guided hepaticogastrostomy with bridging stent placement.
    Endoscopy. 2025;57.
    PubMed        
    
    
12. ZHANG W, Zhang L, Hou S
    Management of short-term recurrent obstructive jaundice after endoscopic ultrasound guided hepaticogastrostomy.
    Endoscopy. 2025;57.
    PubMed        
    
    
13. BAN T, Kubota Y, Hirayama Y, Ando K, et al
    Multi-holed fully covered self-expandable metal stent to dilate a benign hepaticojejunostomy anastomotic stricture.
    Endoscopy. 2025;57.
    PubMed        
    
    

    
    Eur Radiol

14. CHIU SH, Kamaya A, Tse JR
    Letter to the Editor: Early post-treatment imaging enables timely diagnosis of viable hepatocellular carcinomas after selective internal radiation therapy.
    Eur Radiol. 2025 Oct 17. doi: 10.1007/s00330-025-11998.
    PubMed        
    
    
15. WEI H, Jiang H, Lee JM
    Reply to the Letter to the Editor: Early post-treatment imaging enables timely diagnosis of viable hepatocellular carcinomas after selective internal radiation therapy.
    Eur Radiol. 2025 Oct 17. doi: 10.1007/s00330-025-11999.
    PubMed        
    
    

    
    Gastroenterology

16. ORMAN ES, Fortune BE, John BV, Asrani SK, et al
    AGA Clinical Practice Update on the Management of Ascites, Volume Overload, and Hyponatremia in Cirrhosis: Expert Review.
    Gastroenterology. 2025 Oct 20:S0016-5085(25)05959.
    PubMed         Abstract available
    
    

    
    Gastrointest Endosc

17. TAKASAKI Y, Isayama H, Yamaguchi Y, Hagiwara H, et al
    Peroral cholangioscopy-guided laser-stricturoplasty for intrahepatic benign biliary strictures (with video).
    Gastrointest Endosc. 2025 Oct 18:S0016-5107(25)02113.
    PubMed         Abstract available
    
    

    
    Gut

18. YANG Z, Hu Y, Yang C, Li Y, et al
    SMYD2-mediated methylation of STAT1 protects against hepatic ischaemia/reperfusion injury by blocking JAK-STAT1 signalling pathways.
    Gut. 2025 Oct 17:gutjnl-2025-336400. doi: 10.1136/gutjnl-2025-336400.
    PubMed         Abstract available
    
    

    
    Hepatology

19. WALIA N, Hui S, Braude M
    Letter to the Editor: Assessing HCC incidence and surveillance thresholds in non-cirrhotic MASLD.
    Hepatology. 2025 Oct 23. doi: 10.1097/HEP.0000000000001586.
    PubMed        
    
    
20. GRIMAUD E, Gardin A, Ackermann O, Habes D, et al
    Serum bile acid levels predict the development of portal hypertension and high-risk esophageal varices following successful Kasai in biliary atresia.
    Hepatology. 2025 Oct 23. doi: 10.1097/HEP.0000000000001592.
    PubMed         Abstract available
    
    
21. DELGADO ER, Patel P, Tao J, Krutsenko Y, et al
    Glutamine synthetase loss in beta-catenin-mutant hepatocellular carcinoma promotes tumor burden through macrophage metabolic reprogramming.
    Hepatology. 2025 Oct 23. doi: 10.1097/HEP.0000000000001591.
    PubMed         Abstract available
    
    
22. JOHN BV, Bastaich D, Singal AG, Dahman B, et al
    Reply: Assessing HCC incidence and surveillance thresholds in non-cirrhotic MASLD.
    Hepatology. 2025 Oct 20. doi: 10.1097/HEP.0000000000001587.
    PubMed        
    
    

    
    Indian J Gastroenterol

23. JAIN M
    Comment on "Child-Turcotte-Pugh score-based modified anti-tubercular treatment in patients with decompensated cirrhosis with tuberculosis: A two-year retrospective observational study from North India".
    Indian J Gastroenterol. 2025 Oct 23. doi: 10.1007/s12664-025-01898.
    PubMed        
    
    
24. ALEXANDER V, John A, Benjamin S, Akilesh S, et al
    Non-selective beta blockers are well tolerated in pregnancy with portal hypertension.
    Indian J Gastroenterol. 2025 Oct 23. doi: 10.1007/s12664-025-01876.
    PubMed         Abstract available
    
    

    
    Int J Cancer

25. ZHENG Y, Han J, Qu Y, Wang J, et al
    Circulating cell-free DNA methylation biomarkers for hepatocellular carcinoma risk prediction in HIV-positive Nigerian population.
    Int J Cancer. 2025 Oct 23. doi: 10.1002/ijc.70204.
    PubMed         Abstract available
    
    
26. DE SALINS V, Martinez-Tapia C, Gay P, Morel A, et al
    The Fibrosis-4 score is associated with overall mortality and severe haematological toxicity in older patients with cancer: Analysis of two prospective cohort studies.
    Int J Cancer. 2025;157:2506-2520.
    PubMed         Abstract available
    
    
27. LI H, Feng Y, Wang Z, Li X, et al
    Advances in the management of ovarian cancer liver metastasis.
    Int J Cancer. 2025 Aug 16. doi: 10.1002/ijc.70065.
    PubMed         Abstract available
    
    

    
    J Gastroenterol

28. HINO K, Nishina S, Yanatori I
    Ferroptosis: biology and role in liver disease.
    J Gastroenterol. 2025;60:1339-1361.
    PubMed         Abstract available
    
    
29. TAKEMURA Y, Ueda Y, Takemura R, Mita J, et al
    Current status of waitlist mortality and transplant probability for adult candidates with chronic end-stage liver disease for deceased donor liver transplantation under the Model for End-Stage Liver Disease score-based allocation policy in Japan.
    J Gastroenterol. 2025;60:1414-1426.
    PubMed         Abstract available
    
    
30. IWASA T, Miwa T, Utakata Y, Oi M, et al
    Development of overt hepatic encephalopathy increases mortality in patients with cirrhosis: a multicenter retrospective cohort study.
    J Gastroenterol. 2025 Oct 17. doi: 10.1007/s00535-025-02309.
    PubMed         Abstract available
    
    

    
    J Gastroenterol Hepatol

31. FAN C, He X, Zhou Y, Ye C, et al
    The Effects of CD100 Stimulation on Primary Human Hepatocytes (PHHs) and Its Implications in HBV-Related Liver Cirrhosis.
    J Gastroenterol Hepatol. 2025 Oct 21. doi: 10.1111/jgh.70123.
    PubMed         Abstract available
    
    

    
    J Hepatol

32. YUAN H, Zhao L, Yang G, Zhang S, et al
    HBx-induced HSPB1 is a potential therapeutic target owing to its modulation of HBV cccDNA and hepatic immune responses.
    J Hepatol. 2025 Oct 16:S0168-8278(25)02556-5. doi: 10.1016/j.jhep.2025.
    PubMed         Abstract available
    
    
33. CELSA C, Pinato DJ, Cabibbo G
    "Advancing Clinical Trial Design and Patient Care in Hepatocellular Carcinoma".
    J Hepatol. 2025 Oct 17:S0168-8278(25)02558-9. doi: 10.1016/j.jhep.2025.
    PubMed        
    
    
34. GLYNN AM, Faye MD, Gerard IJ, Vanner RJ, et al
    Stereotactic body radiotherapy treatment for hepatocellular carcinoma with extensive macrovascular invasion.
    J Hepatol. 2025 Oct 17:S0168-8278(25)02559-0. doi: 10.1016/j.jhep.2025.
    PubMed        
    
    
35. VAZ J, Nasr P, Helander A, Shang Y, et al
    Phosphatidylethanol levels distinguish steatotic liver disease subgroups and are associated with risk of major liver outcomes.
    J Hepatol. 2025;83:1011-1022.
    PubMed         Abstract available
    
    
36. GHALLAB A, Mandorfer M, Stirnimann G, Geyer J, et al
    Enteronephrohepatic Circulation of Bile Acids and Therapeutic Potential of Systemic Bile Acid Transporter Inhibitors.
    J Hepatol. 2025 May 23:S0168-8278(25)02207-X. doi: 10.1016/j.jhep.2025.
    PubMed         Abstract available
    
    
37. LIU J, Xiao S, Hu S, Huang R, et al
    Dissecting metabolic dysfunction- and alcohol-associated liver disease (MetALD) using proteomic and metabolomic profiles.
    J Hepatol. 2025;83:1035-1045.
    PubMed         Abstract available
    
    
38. ALGUERO-NADAL A, Mol H, Zoppolato E, Kowalczyk W, et al
    Steatotic liver disease induces YAP/TAZ-driven cell competition that can suppress tumor initiation.
    J Hepatol. 2025;83:1142-1155.
    PubMed         Abstract available
    
    
39. TAVAGLIONE F, Diaz LA, Ajmera V, Madamba E, et al
    Clinical utility of phosphatidylethanol to detect underreported alcohol use and enhance steatotic liver disease subclassification.
    J Hepatol. 2025;83:1023-1034.
    PubMed         Abstract available
    
    
40. JAECKEL E, Friedman SL, Hudecek M, Protzer U, et al
    Chimeric antigen receptor (CAR) T-cell therapy: Engineering immune cells to treat liver diseases.
    J Hepatol. 2025;83:1156-1171.
    PubMed         Abstract available
    
    
41. BEUERS U, Banales JM, Karpen S, Keitel V, et al
    History and prospects of bile acid therapies.
    J Hepatol. 2025 Jun 20:S0168-8278(25)02277-9. doi: 10.1016/j.jhep.2025.
    PubMed         Abstract available
    
    
42. PU X, Liu Y, Lyu Z, Zhou Y, et al
    B cells drive CCR5(+)CD4(+) tissue-resident memory T cell cytotoxicity via IL-15Ralpha-IL-15 signaling in primary biliary cholangitis.
    J Hepatol. 2025 Jul 17:S0168-8278(25)02340-2. doi: 10.1016/j.jhep.2025.
    PubMed         Abstract available
    
    
43. TORP N, Israelsen M, Thiele M, Rinella ME, et al
    Phosphatidylethanol in steatotic liver disease.
    J Hepatol. 2025;83:1189-1203.
    PubMed         Abstract available
    
    

    
    Lancet

44. KASEB A, Pawlik TM
    Perioperative camrelizumab plus rivoceranib versus surgery in resectable hepatocellular carcinoma.
    Lancet. 2025 Oct 19:S0140-6736(25)02104-X. doi: 10.1016/S0140-6736(25)02104.
    PubMed        
    
    
45. WANG Z, Fan J, Zhou S, Sun Y, et al
    Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial.
    Lancet. 2025 Oct 19:S0140-6736(25)01720-9. doi: 10.1016/S0140-6736(25)01720.
    PubMed         Abstract available
    
    

    
    Minerva Gastroenterol (Torino)

46. TEJEDOR-TEJADA J, Hermida B, Camblor C, Robles S, et al
    Timing of endoscopy in cirrhotic patients with acute variceal bleeding: a multicenter cohort study.
    Minerva Gastroenterol (Torino). 2025 Oct 21. doi: 10.23736/S2724-5985.25.03930.
    PubMed         Abstract available
    
    

    
    PLoS One

47. HAMAD RS, Elshaer MAA, El-Mahdy HA, Mohammed OA, et al
    Green-synthesized zinc oxide nanoparticles using Echinops spinosus extract: A promising anticancer agent for hepatocellular carcinoma.
    PLoS One. 2025;20:e0331171.
    PubMed         Abstract available
    
    
48. HUANG A, Su M, Zhang S, Zhao C, et al
    Alterations in the gut microbiota of alcoholic cirrhosis patients infected with Clonorchis sinensis in the Pearl River Delta region of China.
    PLoS One. 2025;20:e0334311.
    PubMed         Abstract available
    
    
49. ONO Y, Sakai K, Okamura T, Okada H, et al
    Metabolic dysfunction-associated steatotic liver disease (MASLD) can be a possible predictive factor of incident CKD: NAGALA cohort study.
    PLoS One. 2025;20:e0334720.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

50. GU L, Du Y, Nazmul Hasan M, Clayton YD, et al
    Adipose cullin 3 mediates the antiobesity effect of pan neddylation inhibitors.
    Proc Natl Acad Sci U S A. 2025;122:e2515947122.
    PubMed         Abstract available
    
    

    
    Radiology

51. DENG M, Li Z, Sun L, Wang H, et al
    Liver MRI-derived Proton Density Fat Fraction Predicts Diabetes Risk in Patients with Obesity: A Dose-Response Study.
    Radiology. 2025;317:e250026.
    PubMed         Abstract available
    
    

    
    Transplantation

52. WALLER D, Chinnakotla S, Ramanathan K, Brierton J, et al
    Liver Retransplantation: Identifying Factors and Developing a Risk Prediction Model to Predict Futility in the Modern Era.
    Transplantation. 2025;109:1765-1773.
    PubMed         Abstract available
    
    
53. LIU JY, Liao W, Chen ZY, Liu T, et al
    PKM2 Drives Lactate-mediated Fibrosis in Liver Transplantation.
    Transplantation. 2025 Jun 27. doi: 10.1097/TP.0000000000005461.
    PubMed         Abstract available
    
    
54. KARLINSKI VIZENTIN V, Antunes V, Ferreira Felix I, Florencio de Mesquita C, et al
    Combined Heart and Liver Transplantation in the Failing Fontan: Systematic Review and Single-arm Meta-analysis.
    Transplantation. 2025 May 5. doi: 10.1097/TP.0000000000005400.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.